1. Clinical Overview
Cerebroprotein Hydrolysate is a neurotrophic agent derived from porcine brain tissue. It is a complex mixture of low-molecular-weight peptides, amino acids, and nucleotides. In the Indian market, it is widely prescribed as a neuroprotective and neurorestorative agent for various neurological conditions. It is believed to support neuronal survival, enhance synaptic plasticity, and promote nerve growth factor (NGF) activity. It is administered via intramuscular injection or intravenous infusion.
| Onset | Duration | Bioavailability |
|---|---|---|
| The onset of action is not precisely defined. Clinical effects on cognitive parameters may be observed after several weeks of therapy. | The duration of action is prolonged, with effects potentially lasting for several weeks after a course of treatment, related to its proposed neurotrophic and neuroplastic effects. | Approximately 50-70% following intramuscular administration. Intravenous administration provides 100% bioavailability. |
2. Mechanism of Action
Cerebroprotein Hydrolysate exerts its effects through a multimodal mechanism. It contains biologically active peptides and amino acids that mimic endogenous neurotrophic factors. It is proposed to promote neuronal survival, stimulate neurite outgrowth, enhance synaptogenesis, and improve cerebral glucose utilization. It may modulate neurotransmitter systems, including cholinergic and monoaminergic pathways, and provide substrates for neuronal repair.
3. Indications & Uses
- Post-stroke neurological deficits and rehabilitation
- Vascular dementia
- Alzheimer's disease (as an adjunct therapy)
- Traumatic brain injury sequelae
4. Dosage & Administration
Adult Dosage: 215.2mg once daily via intramuscular injection or slow intravenous infusion. For IV infusion, dilute in 100-250 mL of 0.9% Sodium Chloride Injection. The typical treatment course is 10-20 days, which may be repeated after a break of 2-4 weeks as per physician's advice.
Administration: For IM use: Administer by deep intramuscular injection. Rotate injection sites. For IV use: Administer as a slow infusion over 60-90 minutes. Do not mix with other medications in the same syringe or infusion bag. Use immediately after reconstitution/dilution. Inspect solution for particulate matter or discoloration before use.
5. Side Effects
Common side effects may include:
- Pain, redness, or induration at the injection site
- Mild fever (pyrexia)
- Headache
- Dizziness
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Anticoagulants (Warfarin, NOACs) | Theoretical risk of increased bleeding due to peptide content; monitor INR/clotting parameters. | Moderate |
| Antiepileptic Drugs | May potentially antagonize effects; monitor seizure control. | Moderate |
| CNS Depressants (Alcohol, Benzodiazepines) | Additive sedative effects possible; caution advised. | Mild |
7. Patient Counselling
- Do complete the prescribed course of injections/infusions for optimal benefit.
- Do report any pain, swelling, or redness at the injection site.
- Do inform your doctor about all other medications you are taking.
- Don't self-administer unless specifically trained for IM injections.
- Don't drive or operate heavy machinery if you experience dizziness.
8. Toxicology & Storage
Overdose: Symptoms of overdose are not well-documented but may include exacerbation of known side effects: severe dizziness, hypotension, fever, chills, and possible renal overload symptoms.
Storage: Store below 25°C. Protect from light. Do not freeze. Keep the vial in the outer carton. After reconstitution/dilution, use immediately. Discard any unused portion. Keep out of reach of children.